Search

• Anoro® (umeclidinium/vilanterol) gains marketing authorisation in Europe for the treatment of COPD

  Media

  GSK & THRX announced that the European Commission has granted marketing authorisation for Anoro to relieve symptoms in patients with COPD.

  https://www.gsk.com/en-gb/media/press-releases/anoro-umeclidiniumvilanterol-gains-marketing-authorisation-in-europe-for-the-treatment-of-copd/

  First published: 08 May 2014

• Anoro® Ellipta® (umeclidinium/vilanterol) gains approval in Japan for the treatment of COPD

  Media

  GSK & THRX announced that JMHLW has approved Anoro® Ellipta® (umeclidinium/vilanterol) for the relief of various symptoms with COPD

  https://www.gsk.com/en-gb/media/press-releases/anoro-ellipta-umeclidiniumvilanterol-gains-approval-in-japan-for-the-treatment-of-copd/

  First published: 04 July 2014

• GSK acquires full ownership of its Indonesian Consumer Healthcare business

  Media

  GSK has acquired full ownership of its Indonesian Consumer Healthcare business

  https://www.gsk.com/en-gb/media/press-releases/gsk-acquires-full-ownership-of-its-indonesian-consumer-healthcare-business/

  First published: 28 March 2014

• GSK announces submission to U.S. regulatory authorities for Promacta™ (eltrombopag) for severe aplastic anaemia

  Media

  GSK announced the submission of a supplemental New Drug Application (sNDA) to the U.S. FDA for Promacta™ (eltrombopag).

  https://www.gsk.com/en-gb/media/press-releases/gsk-announces-submission-to-us-regulatory-authorities-for-promacta-eltrombopag-for-severe-aplastic-anaemia/

  First published: 28 February 2014

• ViiV Healthcare announces new initiatives to improve access to dolutegravir: licence to the Medicines Patent Pool

  Media

  ViiV announced new collaborations to increase access to its HIV medicine, dolutegravir ( Tivicay®), just after approval by EMA & FDA.

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-new-initiatives-to-improve-access-to-dolutegravir-licence-to-the-medicines-patent-pool/

  First published: 01 April 2014

• GSK appoints Mr Urs Rohner to its Board as a Non-Executive Director

  Media

  GSK today announced the appointment of Mr Urs Rohner to its Board as a Non-Executive Director, effective 1 January 2015.

  https://www.gsk.com/en-gb/media/press-releases/gsk-appoints-mr-urs-rohner-to-its-board-as-a-non-executive-director/

  First published: 03 October 2014

• GSK announces EU regulatory submission seeking extended indication for ambrisentan (Volibris®) in pulmonary arterial hypertension

  Media

  GSK announced that it has filed a regulatory submission to the EMA for a variation to the Marketing Authorisation for ambrisentan(Volibris®)

  https://www.gsk.com/en-gb/media/press-releases/gsk-announces-eu-regulatory-submission-seeking-extended-indication-for-ambrisentan-volibris-in-pulmonary-arterial-hypertension/

  First published: 11 December 2014

• GSK signs up to UK Government’s Public Health Responsibility Deal

  Media

  Pledge to reduce the sugar and calorie content of Lucozade Energy and Ribena products.

  https://www.gsk.com/en-gb/media/press-releases/gsk-signs-up-to-uk-government-s-public-health-responsibility-deal/

  First published: 22 January 2013

• GSK welcomes launch of the UK Government’s Life Sciences Sector Deal

  Media

  New £40 million GSK investment in genomic research

  https://www.gsk.com/en-gb/media/press-releases/gsk-welcomes-launch-of-the-uk-government-s-life-sciences-sector-deal/

  First published: 06 December 2017

• GSK completes major three-part transaction with Novartis

  Media

  GSK has acquired Novartis’s global Vaccines business (excluding influenza vaccines) for an initial cash consideration of $5.25 billion

  https://www.gsk.com/en-gb/media/press-releases/gsk-completes-major-three-part-transaction-with-novartis/

  First published: 02 March 2015